compound screening

BioAscent is a provider of integrated drug discovery services based at the former Organon/MSD R&D site in Newhouse, Scotland, UK. Founded in 2013, its services include assay development, target analysis, compound screening, medicinal and synthetic chemistry, computational chemistry, DMPK, protein science and compound management, with access to in-house diversity and fragment libraries.

assay developmentbiophysicscompound managementcompound storage and logisticscomputational chemistryDMPKhigh throughput screeningin silico discoveryLC-MSliquid handlingmedicinal chemistryNMRprotein productionpurificationstructural biologysurface plasmon resonancesynthetic chemistry

Bioprinting Laboratories Inc. develops microarray three-dimensional (3D) bioprinting technology and produces injection-molded pillar/perfusion plates and accessories for static and dynamic culture of 3D cells and organoids, as well as bioprinted human organoids derived from pluripotent stem cells. Its products support 3D cell/tissue culture and predictive compound screening for the pharmaceutical, cosmetics, and chemical industries, and it offers related toxicity/efficacy assessment services.

3D cell and organoid cultureCRISPRai gene regulation in organoidsdisease modelinginjection moldingmicroarray 3D bioprinting

Boster Biological Technology (Boster Bio) is a manufacturer and supplier of antibodies, ELISA kits, and recombinant proteins for life science research. The company offers over 40,000 antibodies validated for IHC, WB, ELISA, and FC, and more than 2,000 ELISA kits including Picokine® and EZ-Set® lines. Boster also provides custom antibody and recombinant protein production, assay, and analytical services.

AAV packagingantibody conjugationantibody productioncustom antibody developmentELISA assay developmentflow cytometry servicesgene synthesisimmunohistochemistry (IHC) servicespeptide synthesisqPCR servicesrecombinant protein expressionWestern blotting services

Dexorgen, Inc. is an advanced biotechnology company headquartered in Maryland focused on drug discovery. It provides live cell based assays for novel compound screening, including patented ACTOne-based phosphodiesterase (PDE) and G-protein coupled receptor (GPCR) cell lines, and states it is the first in the world to produce commercially available cell lines to screen for compounds targeting PDEs. It also provides biochemical assay kits and specialty dyes, and participated in the federal Tox21 collaboration with NIH, EPA and FDA.

assay developmentcell engineering with CRISPR and shRNAcontract researchlive cell based assaysmechanism of action characterizationprimary cell culturestable cell line development

Creative Scientist, Inc. develops customized New Approach Methodologies (NAMs), advanced human cell models, and scalable experimental platforms for drug discovery, efficacy assessment, safety evaluation, disease modeling, and mechanism-of-action studies. The company offers assay development, drug discovery and screening, drug safety and toxicology, disease modeling, advanced cell models, and molecular biology and analytical services. It also offers Volteer-96, an automated TEER measurement device, and VecStem endothelial cell culture media.

antibody-drug conjugatesantibody-RNA conjugatesassay developmentbarrier function assessmentcytotoxicity assessmentdisease modelingformulation stability testinghepatotoxicity assessmenthigh content imaginglead optimizationmechanism-of-action studiesparticle characterizationprotein expression and purificationTEER measurementvascular safety assessmentvirus-mediated gene delivery

Cytoskeleton, Inc. is a supplier of advanced cell biology and protein products, offering user-friendly kits, specialty reagents, and custom services. Since 1994 it has been involved in small G-protein research, launching the first line of small GTPase reagents in consultation with Dr. Alan Hall. The company provides products with over 50,000 product citations and 30+ years serving the scientific community.

assay developmentcustom servicesprotein purificationtarget validation

InvivoSciences, Inc. (IVS) is a precision medicine company personalizing the drug development process using patient-derived and gene-edited human samples, including an automated, scalable, functional 3D engineered micro-human heart tissue platform. It integrates cell and tissue handling automation, tissue phenotyping assays, computational biology (AI), and human organ/tissue data to identify safety and efficacy profiles of treatments. Founded in 2001 in St. Louis, Missouri, with technology licensed from Washington University, and moved to Wisconsin in 20

3D engineered micro-human heart tissueautomated cell and tissue handlingbiomechanical assayscardiac toxicity assessmentscomputational biology/AIgene editinghigh-throughput phenotypinginduced pluripotent stem cell (iPSC) technologyoptical devices

KBS Research is a physician-led research and development company founded in 2012 by Dr. Kenneth Brown, MD, and Brandi Scott-Hoy, originating in a Texas gastroenterology practice. It combines gastroenterology, microbiome science, polyphenol chemistry, and human clinical research to develop polyphenol-based formulations addressing mechanisms behind digestive and metabolic dysfunction, including fermentation, pressure, motility, and microbiome balance.

clinical researchformulation developmentpeer-reviewed researchstructured human studies